Stockhead “90 Seconds With” Interview

Anatara Lifesciences Ltd (ASX:ANR) CEO Steve Lydeamore was recently interviewed by Stockhead, for its “90 Seconds With” interview series, providing an overview of the Company’s gastrointestinal health products, as well as the upcoming newsflow for the next 12months.

1. Can you provide our investor audience with an overview of Anatara Lifesciences?

2. What can investors expect to see from Anatara Lifesciences over the next 6-12 months?

Anatara Lifesciences (ASX:ANR) is developing and commercialising a range of gastrointestinal health products focused on animal and human health. The company’s lead product, Detach, is a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour), which affects livestock. Anatara is also developing Gastrointestinal ReProgramming (GaRP), a microbiome-targeted dietary supplement. The product is designed to address the primary underlying factors associated with gastrointestinal disorders such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).

Digestive Health Supplements Market Segmentation Detailed Study with Forecast to 2028

19 JANUARY 2020

The science behind digestive health has advanced stridently over the past couple decades. Gut problems and digestive diseases have no longer remained under the sole ambit of pharmaceuticals.

Global Digestive Health Supplements Market: Notable Developments
Life sciences companies in various parts of the world are striving to come out with supplements with novel action on gut health. Recently, an Australian-based life sciences company Anatara Lifesciences has come out with a health supplement that has the potential to reprogram the gut microbiome.

Please click on the link below for the full article:

Digestive Health Supplements Market Segmentation Detailed Study with Forecast to 2028

Anatara takes next step in testing its answer to US$8 billion global IBS issue

TechInvest Magazine Online

Anatara Lifesciences (ASX:ANR) has met the projected milestone to finalise a draft protocol for a human clinical trial for its GaRP dietary supplement in the treatment of irritable bowel syndrome (IBS).

CEO, Steven Lydeamore said Anatara has commenced the process of selecting a clinical research organisation (CRO) to undertake the clinical trials.

“There is a major unmet medical need and significant market opportunity for an evidence-based dietary supplement for IBS,” Mr Lydeamore said.

Click the following link for access to the full article:

Anatara takes next step in testing its answer to US$8 billion global IBS issue

Pitt Street Research Life Sciences Conference Presentation

Anatara Lifesciences Ltd (ASX:ANR) CEO Steve Lydeamore presented to investors at the Pitt Street Research Life Sciences Conference in Sydney last month. Steve speaks to the Anatara story and the exciting year we have ahead with corporate milestones on both our human and animal health product opportunities.

Anatara is currently evaluating a range of evidence-based gastrointestinal consumer health products with a view to expand its current pipeline through in-licencing and distribution. In parallel, the Company continues to remain on-track to announce its human clinical trial protocol and the latest results from the second cohort as part of its current pre-clinical animal studies for its Gastrointestinal ReProgramming dietary supplement, bringing the Company closer to partnering in 2020.

The Company remains focused on building a pipeline of evidence-based human gastrointestinal health products which will provide real outcomes for patients and drive value for its shareholders.

Inflammatory Bowel Disease Insight Report: Current Therapies, Drug Pipeline and Outlook

Anatara Lifesciences’ Gastrointestinal ReProgramming (GaRP) dietary supplement was recently included in Biospace’s latest Inflammatory Bowel Disease Insight Report as a preclinical candidate in the IBD drug pipeline.
Anatara Lifesciences’ lead human health product is referred to as GaRP (Gastrointestinal ReProgramming). The GaRP product is a microbiome-targeted multi-component dietary supplement that has been designed to address the primary underlying factors associated with IBD and IBS. It is being positioned as an adjunct to existing therapies and not to replace existing prescription medications. Antara has completed the preclinical program, which provided strong scientific evidence that GaRP can combat the underlying causes of chronic bowel conditions, including inflammation and dysbiosis of the microbiome.
Click the following link for access to the full article:

ABN Newswire CEO Interview

Anatara Lifesciences Ltd (ASX:ANR) CEO Steve Lydeamore is interviewed by ABN Newswire, and talks about the human trials as well as the product pipeline for next year.

Anatara recently released an exciting announcement to the market having received statistically significant efficacy data from their in vivo mouse studies and further positive in vitro proof of concept data for its Gastrointestinal ReProgramming (GaRP) product. GaRP is a proprietary dietary supplement designed to restore and maintain a healthy human gut and microbiome.

CEO interview for Morgan’s “Under the Microscope” podcast series

Under the Microscope Podcast with Scott Power


Anatara Lifesciences CEO Steve Lydeamore sat down with Morgans healthcare analyst Scott Power this week for the “Under the Microscope” podcast series, speaking to Anatara’s recent proof of concept in vitro and in vivo results, the huge unmet medical need for complementary medicines in the gut health space and the Company’s next steps towards a human clinical trial and partnering in 2020.

Listen to the podcast interview here.

Morgans is Australia’s largest national full-service stockbroking and wealth management network with more than 240,000 client accounts, 500 authorised representatives and 950 employees operating from offices in all states and territories.

NUTRAingredients “Reprogramming the microbiome”

Reprogramming the microbiome: Anatara Lifesciences targets the human health space with dual targeted formulation

21 OCTOBER 2019 NUTRAingredients

Tingmin Koe

Anatara CEO, Steven Lydeamore, was recently interviewed by NUTRAingredients Editor, Tingmin Koe, about how Anatara’s Gastrointestinal ReProgramming (GaRP) dietary supplement has the ability reduce inflammation, address microbiome dysbiosis and promote mucosal healing. There is a significant unmet medical need for products that can address these factors which contribute to the primary symptoms experienced by patients suffering chronic bowel conditions such as irritable bowel syndrome and the inflammatory bowel diseases.

Click the following link for access to the article –

NutraIngredients has been the leading online news source for the nutrition industry for more than 15 years, providing a 360-degree view of the global functional food and supplement market, spanning everything from investment, incubation and innovation, to ingredients, food science and product formulation, labelling, litigation, regulation, consumer trends, new products and new technology.

Stockhead’s “The Health Kick” podcast with Tim Boreham

The Health Kick Podcast with Tim Boreham: Anatara Lifesciences


Anatara Lifesciences CEO Steve Lydeamore sat down with Tim Boreham this week for Stockhead’s new podcast series, “The Health Kick”, speaking to how Anatara plans to stand out in the gut health market, solve scours in livestock and the future of antibiotics in the food chain.

Listen to the podcast interview here.

On mobile? Click here to listen with Apple podcasts, here for Spotify or here for Google Podcasts.

Stockhead is a free, journalistic news service dedicated to covering the stories of emerging, ASX-listed companies.

Australasian Biotechnology – The role of complementary medicines in managing chronic bowel conditions

In the latest edition of the Australasian Biotechnology Journal, vol29, no2, Anatara CSO, Dr Tracey Brown, talks to the role of complementary and alternative medicines in managing chronic bowel conditions such as Irritable Bowel Syndrome and Inflammatory Bowel Disease, and how Anatara hopes to demonstrate its Gastrointestinal ReProgramming (GaRP) dietary supplement has the ability to induce and maintain remission in patients suffering from chronic bowel disorders.

Click the following link for access to the complete journal edition-

Dr Boreham’s Crucible “Anatara Lifesciences”


Anatara’s greater prospects lie with human health, as a remedy for the common but difficult-to-treat afflictions of irritable bowel syndrome and inflammatory bowel disease(ulcerative colitis and Crohn’s disease).

Mr Lydeamore notes that gut health is “very topical”, which is an understatement given the range of digestion-related ‘wellness’ products purveyed by the likes of Blackmores and Suisse. “If you do a Google search on the topic you will get more than 400 million hits,” he says.

He’s right: your columnist’s rigorous cross-checking of this claim reveals 530 million online references.

For the full article, please click here –
Dr Boreham’s Crucible – Anatara Lifesciences

Biotech Daily “Bioshares Gut Health & the Microbiome Session Report”


The companies which presented in the Gut Health and Microbiome session at the 2019 Bioshares Biotech Summit are approaching the problem of untangling the complexity of the microbiome from different directions.

Anatara Lifesciences – Seeking Clinical Validation for GaRP

Steve Lydeamore, CEO of Anatara Lifesciences, outlined their strategy of utilising a specific dietary element to target the interface of the microbiome and the body. This product, named GaRP (Gastrointestinal Reprogramming Product), acts to “remove bacteria with pro-inflammatory properties” and “stimulate mucosal healing”.

The function of this product seems to be similar to that of a prebiotic, an emerging but competitive niche in the gastro-intestinal health market.

Anatara Lifesciences’ strategy of seeking clinical validation for this product will do well to set it apart from other prebiotics which usually trade as nutritional supplements.

To read the full article, please click 190731 – Bioshares802 Summit Summary

Finance News Network Interview with CEO

Anatara Lifesciences CEO Steve Lydeamore sat down with Anna Napoli at Finance News Network. The Finance News Network is Australia’s largest provider of online business and finance news.

Steve sat down with Anna to talk about our upcoming clinical studies and lead Gastrointestinal Reprogramming dietary supplement product candidate for Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD). Steve discusses the completion of our pre-clinical in vitro proof of concept studies, which demonstrated our products’ ability to address three shared characteristics of these conditions – inflammation, impaired intestinal barrier function and mucosal damage. The timeframe for partnering our dietary supplement product candidate is 18 to 24 months.

Pitt Street Research Interview with CEO

Stuart Roberts of Pitt Street Research recently sat down with Steve Lydeamore, CEO of Anatara Lifesciences (ASX: ANR) to talk about the path to market for the company’s new dietary supplement product, called GaRP (gastrointestinal reprogramming).

Based on bromelain, GaRP has shown promise as a potential treatment for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Anatara believes there is significant upside for this product given the lack of strong treatment alternatives and the high prevalence of IBS and IBD.

Morgans Interview with Anatara CEO

Anatara Lifesciences CEO Steve Lydeamore sat down with Scott Power, Senior Research Analyst at Morgans Financial Limited yesterday to talk about the Company’s plans in human gastrointestinal health; developing a unique dietarysupplement to help IBS and IBD patients in the growing gut health market.

Proactive Investors CEO Interview

Anatara Lifesciences is pleased to release a copy of Anatara CEO, Steve Lydeamore, recent interview with Ky Chow of Proactive Investors Australia about the healthcare company’s renewed focus on human health, targeting the 11% of Australians affected by irritable bowel syndrome (IBS).

Lydeamore says the biotech firm’s dietary supplement is unlike other gut health products at the pharmacy because it seeks to repair lining of the gut.

ABN Newswire CEO Interview

Anatara Lifesciences is pleased to release a copy of Anatara CEO, Steve Lydeamore, recent interview with Tim McKinnon of ABN Newswire on the development of its Irritable Bowel Syndrome (IBS) dietary supplement to address the growing need for a product that addresses the full range of IBS symptoms.

Stockhead “This small cap biotech proves it is possible to have more women than men on a board”

Angela East

What better time than International Women’s Day to highlight that is entirely possible to have more women in leadership roles?

Today, all around the world, people are recognising and celebrating womens’ achievements and working to knock down the barriers that still exist in the ongoing fight for gender equality.

One ASX-listed small cap biotech has proven it is possible to not only have women in leadership positions, but it is quite possibly the only ASX-listed company to have had an all-female board at one point.

For the full article, please click here.

Stockhead “IBS sufferers – Anatara Lifesciences reckons it has a breakthrough formula to help”

Sam Jacobs

Australian biotech Anatara is busy working on its next big idea in the market for digestive health products.

The company says it’s concluded a successful proof of concept study for a dietary supplement that treats gastrointestinal problems.

For the full article, please click here.

Mergermarket “Anatara Lifesciences seeks deals to bolster human health”

Louise Weihart in Sydney

Anatara Lifesciences [ASX:ANR], an Australian developer of treatments for gastro-intestinal conditions with unmet medical need, is actively seeking deals to bolster its gastro-intestinal pipeline as it moves its focus to human health, said new Chief Executive Officer Steven Lydeamore.

For the full article, please click here –
190121 – Mergermarket – Anatara Lifesciences seeks deals to bolster human health

Biotech Dispatch “New CEO for Anatara Lifesciences”


Anatara Lifesciences (ASX:ANR) has announced the appointment of Steven Lydeamore as its CEO.

The company is developing non-antibiotic oral solutions for gastrointestinal diseases in animals and humans.

Anatara’s Chair, Sue MacLeman, said the appointment is a key step in its development and transition to its focus on human health.

“We are very fortunate to have attracted someone of Steven’s calibre to lead Anatara at this important stage of the Company’s journey,” said Ms MacLeman. “Steve has demonstrated through his previous roles that he has the ability to successfully commercialise products on a global scale, driving growth and shareholder value.

The full article can be read here.

Gazette APVMA No.22

6 NOV 2018 Australian Pesticides and Veterinary Medicines AuthorityAPVMA Gazette

The APVMA Gazette No. 22 published details of the registration of Detach as a veterinary chemical product, which has now been granted by the APVMA.

Application no.: 108133
Product name: Detach
Active constituent/s: 670 mg/g bromelain
Applicant name: Anatara Lifesciences Ltd
Applicant ACN: 145 239 872
Summary of use: For aid in the control of scour and has positive health benefits in weaned piglets from 3 weeks of age and help increase survivability of scouring pre-weaning piglets
Date of registration: 26 October 2018
Product registration no.: 83368
Label approval no.: 83368/108133

181106 APVMA Gazette No. 22, 6 November 2018

Biotech Daily – ANATARA Appoints Product Development Advisory Board



Anatara says it has appointed a product development advisory board for its non-antibiotic, pineapple stem bromelain-derived gastro-intestinal health programs.

Anatara said the board would be chaired by Prof Peter Gibson and comprise Dr Rebecca Burgell, Dr Jakob Begun, Prof Barry Campbell and Prof Simon Keely and provide advice on issues relating to research priorities, strategies and product development programs.

Anatara fell two cents or five percent to 38 cents.

To read the full article, please click here: 181023 BD Biotech Daily – PDAB Appointments




Anatara says it has appointed Sue MacLeman and Dr Jane Ryan as non-executive chair and non-executive director, respectively, from September 1, 2018.

Anatara said Ms MacLeman would replace Dr Jay Hetzel who had been interim chairman since the retirement of co-founder Dr Mel Bridges earlier this year (BD: May 17, 2018). The company said that following the decision “to focus on the development of products and technologies in the human health sector … [it had] undertaken an extensive search to identify new directors with the relevant background and experience which has resulted in these appointments”.

To read the full article, please click here: 180829 BD Biotech Daily – New Board Appointments

Dr Boreham’s Crucible – Anatara Lifesciences


If there’s ever a case of the devil being in the detail, it’s the animal and human health outfit’s fall from investor grace after releasing an investor presentation on May 15 about its newly-inked animal health distribution deal with global giant Zoetis. Anatara shares lost almost 40 percent over the next two trading days, because the disclosed financial terms simply were not as tasty as investors expected. At least the company managed to forge a deal, unlike so many other biotechs.

Anatara’s interim CEO Dr Tracie Ramsdale said the company was pleased with the Zoetis deal because it was expanded to include multiple livestock, rather than just pigs.

To read the full article, please click here: 180820 – Dr Boreham’s Crucible – ANR Aug 17, 2018

Small Caps “Anatara Lifesciences secures Zoetis catalyst for its novel Detach product”


Anatara Lifesciences secures Zoetis catalyst for its novel Detach product

Biotechnology company Anatara Lifesciences (ASX: ANR) has teamed up with animal health developer Zoetis Inc. to develop, manufacture and distribute its Detach product.

The news is significant given that Zoetis has over 60 years’ experience in the sector and currently derives almost two thirds of its US$5.3 billion annual revenue from farm animal health products.

The exclusive licensing agreement will also include marketing of Detach, as a non-antibiotic approach to aid in the control of diarrhoeal disease – otherwise known as ‘scour’ – in livestock and horses.

To read the full article please click here:

Stockhead “Whiff of success for Anatara”


Whiff of success for Anatara as giant Zoetis takes diarrhoea treatment global

The world’s biggest animal health company Zoetis has decided to take an Australian horse diarrhoea treatment global.

Shareholders didn’t pooh-pooh the news, sending the stock up 19 per cent to $1.72. The shares cooled to $1.60 by 12.30pm AEST.

Zoetis — which is listed on the New York Stock Exchange at a value of $US40 billion — has signed an exclusive licence with Anatara Lifesciences (ASX:ANR) for its non-antibiotic diarrhoeal treatment for livestock and horses.

To read the full article please click here:

Courier-Mail “Anatara frustrated at long government delays”


Brisbane-based drug developer Anatara Lifesciences has unleashed frustration at long Australian government delays in clearing its veterinary treatments.

Anatara has labelled the hold ups as “ridiculous” with the biotechnology company still awaiting a 2016 application to bring its pig diahorrea drug to market.

A copy of the full article can be read here: 180225 Courier-Mail – Anatara frustrated at long delays

Biotech Daily “FDA okays Detach-Treated pigs ‘for human food’



Anatara says that the US Food and Drug Administration has provided “complete” letter for the technical section of its human food safety submission.

Anatara is developing its pineapple stem, bromelain-derived Detach as a non-antibiotic treatment for pig and human diarrhoea.

Please click here for the full article: 180205 BD Biotech Daily – Anatara

Courier Mail “Anatara aims to launch its much-delayed pig-poo drug next year in Australia”


Anatara aims to launch its much-delayed pig-poo drug next year in Australia

ANATARA is hoping its delayed-pig diarrhoea treatment will be on the Australian market next year – and it’s even developed a new dosage gun to help boost sales.

“We’re all set to launch in Australia,” Anatara chairman Mel Bridges told investors at the Brisbane-based company’s annual general meeting last week.

The company has a submission with Australian regulators for its product and Mr Bridges said dealings with bureaucrats had gone smoothly with no red flags raised.

Anatara uses a substance derived from pineapples to help stop diarrhoea in pigs, and is marketing the substance as an alternative to antibiotics.

The full article can be read here: 171120 – Courier Mail – Anatara aims to launch its much-delayed pig-poo drug next year in Australia

CommSec Executive Series Interviews CEO Mel Bridges

Anatara Lifesciences Chairman and CEO Mel Bridges sat down with Tom Piotrowski, for CommSec’s Executive Series this month to talk about the current negotiations with #1 global animal health company, Zoetis, regarding a commercial agreement for the worldwide development, distribution and marketing of ANR’s Detach product, in addition to the submission of the Company’s dossier to the Australian Pesticides and Veterinary Medicines Authority (APVMA), seeking regulatory approval to register Detach for commercial marketing in Australia.

Share Cafe “Anatara Investors Look To Pig Out”


Porkers of the world rejoice! If Anatara’s drug rollout goes to plan, soon their short lives in the sty will be healthier and just that little bit longer.

Anatara has won the support of global animal health arm Zoetis, a Pfizer spin-off company that has exercised an option to develop Anatara’s porcine treatment Detach.

The commercial terms are yet to be negotiated, but if it pans out as expected Zoetis will assume all the ongoing costs and Anatara will pocket some fat milestone and royalty cheques.

To read the full article please click 170825 Anatara Investors Look To Pig Out – Share Cafe

ABC Landline Story “How pineapples could protect piglets from infection”

Diarrhoea can be deadly in pig farming. Scour, as it’s called in the industry, kills tens of thousands of piglets every year. It’s traditionally been treated with antibiotics, but a Queensland scientist has developed a powerful, natural alternative from an extract found in pineapple stems

The full story on Anatara and Detach™ was featured on Landline, today (19/03/17) and can be viewed online here.

Feed Navigator “Piglet diarrhea: Australian player seeks regulatory backing for antibiotic alternative”

Jane Byrne

Piglet diarrhea: Australian player seeks regulatory backing for antibiotic alternative

Anatara has submitted an application to register a product, which is based on a natural extract from pineapple roots called bromelain, to control diarrhea in piglets, with the Australian Pesticides and Veterinary Medicines Authority (APVMA).

Click here for access to the full article:

Anatara interviewed for The CEO Sessions

Anatara Lifesciences is pleased to release a copy of Dr Mel Bridges, CEO & Chairman, recent interview with the Financial News Network (FNN) as part of the ASX The CEO Sessions in Sydney on 21st June 2016.

Please click here to view the FNN interview and corresponding ASX presentation.

Anatara CSO interviewed for the CommSec Executive Series

CommSec’s Tom Piotrowski speaks with Anatara Lifesciences (ANR) Chief Scientific Officer, Dr Tracey Mynott about its non-antibiotic treatment for gastrointestinal diseases in production animals.
The pair also discuss ANR’s exclusive deal with the world’s largest animal health company Zoetis, and the 400% jump in its share price over the past year.

Anatara listing day video

Float Watch in The Australian

Anatara Lifescience’s impending listing on the Australian Securities Exchange has been discussed in the Float Watch section of Australia’s only daily broadsheet newspaper The Australian.
Analyst Tim Morris, from, notes that the global appetite for pork is strong as Anatara develops Detach™, our non-antibiotic treatment for diarrhoea in pigs.
He says Anatara controls intellectual property associated with an earlier formulation of Detach™ and that Anatara has further developed the therapy in preparation for field trials.
Read more here.

Obama Administration acts to combat antimicrobial resistance

US President Barack Obama has issued an Executive Order that aims to combat the rise of antibiotic resistant bacteria that represent a serious threat to public health and the economy.

It says the US Federal Government will work domestically and internationally to “detect, prevent, and control illness and death related to antibiotic-resistant infections by implementing measures that reduce the emergence and spread of antibiotic-resistant bacteria and help ensure the continued availability of effective therapeutics for the treatment of bacterial infections”.

Measures to tackle antimicrobial resistance include eliminating “the use of medically important classes of antibiotics for growth promotion purposes in food-producing animals”.

The Executive Order can be found here.

A report to the President on combating antibiotic resistance by the President’s Council of Advisors on Science and Technology can be found here.

Anatara Lifesciences in The Australian newspaper

The Anatara team met senior business journalist Tim Boreham from The Australian newspaper recently to brief him on Anatara and our plans. He notes we’re raising $7 million from investors and that we’re intending to conduct new trials to get Detach re-registered in Australia. He suggests people read our prospectus when it’s lodged.

Read more »

Pigs poo and pineapples could change the world

Anatara’s chief scientific officer Dr Tracey Mynott was interviewed by ABC Radio Brisbane about how DetachTM was created and how treating diarrhoea in pigs could lead to treatments for humans.

To listen to the interview, click here.

UK Royal Pharmaceutical Society recommends better stewardship around antibiotic use

The United Kingdom’s Royal Pharmaceutical Society has recommended better stewardship in the use of antibiotics be encouraged in the wake of growing international concerns about the rise of antimicrobial resistance.

The recommendation is one of seven the society makes in a report discussing challenges around developing new medicines, improving existing medicines and making better use of the ones already available.

“The increasing development of resistance to currently available antibiotics is a potentially serious threat to public health,” the report, titled New Medicines, Better Medicines, Better Use of Medicines, says.

It says the “profound consequences of antibiotic resistance for individual patients and for society create an ethical and moral imperative to protect public health by all reasonable means”.

Calls for global group to tackle antimicrobial resistance

Two leaders in human health have called for the
creation of a global organisation to tackle the growing threat of
antimicrobial resistance.

Mark Woolhouse, professor of infectious disease
epidemiology in the Centre for Immunity, Infection & Evolution at
the University of Edinburgh, and Jeremy Farrar, director of the global
health charity Wellcome Trust, have written in Nature seeking a
organisation similar to the Intergovernmental Panel on Climate Change.

“What is required is committed and coordinated action
on the root causes of resistance: the misuse of antimicrobials, the
paucity of development of new drugs and the lack of alternatives,”
they write.

“Guidelines must be implemented to improve the use of existing drugs;
the scientific and business worlds need incentives and a better
regulatory environment to develop new drugs and approaches, and those
working in both the animal and human sectors need education and
incentives to help them to change their ways.” Read more »

Factory farms, antibiotics and superbugs: Lance Price at TEDxManhattan

Lance Price is a public health researcher who works at the interface between science and policy to address the growing crisis of antibiotic resistance. To view his talk, delivered on March 11, 2014 in Manhattan, click here.